Eyenovia, Inc. Prices Public Offering of Common Stock

Stock Information for Eyenovia Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Eyenovia Inc.

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi(TM) and Clobetasol Propionate Ophthalmic Suspension
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.